Turn Therapeutics Inc. Common Stock
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditi… Read more
Turn Therapeutics Inc. Common Stock (TTRX) - Total Liabilities
Latest total liabilities as of June 2025: $2.56 Million USD
Based on the latest financial reports, Turn Therapeutics Inc. Common Stock (TTRX) has total liabilities worth $2.56 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Turn Therapeutics Inc. Common Stock - Total Liabilities Trend (2023–2024)
This chart illustrates how Turn Therapeutics Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Turn Therapeutics Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Turn Therapeutics Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KALPATARU
NSE:KALPATARU
|
India | ₹134.14 Billion |
|
Novagant Corp
PINK:NVGT
|
USA | $358.20K |
|
NEW HOPE CORPN (OD8.SG)
STU:OD8
|
Germany | €925.42 Million |
|
BYD ELECTRONIC (4BY.SG)
STU:4BY
|
Germany | €57.89 Billion |
|
TMP Group S.p.A.
F:A72
|
Germany | €3.11 Million |
Liability Composition Analysis (2023–2024)
This chart breaks down Turn Therapeutics Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Turn Therapeutics Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Turn Therapeutics Inc. Common Stock (2023–2024)
The table below shows the annual total liabilities of Turn Therapeutics Inc. Common Stock from 2023 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.23 Million | +15.49% |
| 2023-12-31 | $1.93 Million | -- |